IQVIA Holdings has delivered strong share-price gains in recent years, and the latest business updates keep attention firmly on what that current valuation implies about its cash flows. With the stock now trading around US$279, the real issue for you is whether the cash the business can generate over time supports that price.
The issue now is whether IQVIA Holdings' current share price is justified by the cash flows implied in its intrinsic value estimate using a Discounted Cash Flow (DCF) approach.
If you want a wider set of ideas built around similar valuation questions, a focused stock screen is a useful next step. You can start with 29 high quality undervalued stocks.
The Discounted Cash Flow (DCF) model here focuses on the cash IQVIA Holdings can return to shareholders over time. Latest twelve month free cash flow sits at about $2.2b, and the projections used in this DCF assume that IQVIA keeps generating growing cash flows rather than a one off spike or slump. Those future estimates reach into the early 2030s and point to a business treated as a long term compounder of cash, not a turnaround story.
The DCF outcome suggests IQVIA’s estimated intrinsic value is meaningfully above today’s share price of $279.36, so the cash flow profile used in the model implies more value than the market is currently recognising. Because the expanded partnership with Veeva Systems and the higher 2026 outlook both lean on IQVIA’s clinical development capabilities and large backlog, the market may be underpricing how long these cash flows could persist. Find out what IQVIA Holdings could be worth using our Discounted Cash Flow (DCF) estimate.
Narratives pick up where the IQVIA Holdings valuation puzzle leaves off. They spell out what would need to happen to IQVIA Holdings' growth, profitability and earnings for the stock to be worth materially more or less than today’s price. Each one links its number to a clear view on how growth, margins and risk could evolve, giving you something concrete to revisit as fresh information arrives on Simply Wall St’s Community page.
Community views on IQVIA Holdings are split between those who see more upside in the current setup and those who think expectations already look full.
Bull case: 5% undervalued
"Accelerated adoption and scaling of IQVIA Holdings AI agents, with 294 agents now deployed across 90 use cases and embedded in workflows for 19 of the top 20 pharma companies, supports further automation and differentiation that can feed into revenue growth and help protect net margins…"
Discover why this Narrative puts IQVIA Holdings at 5% undervalued.
Bear case: roughly fairly valued
"Although IQVIA Holdings is positioning its AI agents across hundreds of clinical and commercial use cases with most large pharma already engaged, wider client adoption of in house AI tools could still redirect data management and analytics spend away from external providers and compress future revenue and net margin growth if contracts are re scoped or not renewed…"
Explore why this Narrative puts IQVIA Holdings at roughly fairly valued.
Numbers on a screen tell you what IQVIA Holdings costs, but the people steering the business, how they think, and how they are rewarded can heavily influence what those numbers become over time. See who runs IQVIA Holdings and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com